Vnitr Lek 2013, 59(2):113-118

Practice guideline and trends for immunosuppressive treatment of glomerulonephritides according to KDIGO (Clinical Practice Guideline for Glomerulonephritis)

Ľ. Podracká1,*, K. Matoušovic2
1 I. klinika detí a dorastu Lékárskej fakulty UPJŠ a DFN Košice, Slovenská republika, prednostka prof. MUDr. Ľudmila Podracká, CSc.
2 Interní klinika 2. lékařské fakulty UK a FN Motol Praha, přednosta prof. MUDr. Milan Kvapil, CSc., MBA

We summarize recommendations for glomerulonephritis treatment, established by internationally recognized experts in the field and sponsored by KDIGO (Kidney Disease Improving Global Outcomes). Up till now, the KDIGO review has been the most prestigious analysis of therapeutic trials on immunosuppressive treatment of glomerulonephritides. The 167 recommendations addresses the following forms of glomerulopathies: steroid-sensitive nephrotic syndrome and steroid resistant nephrotic syndrome in children; minimal change disease and idiopathic focal segmental glomerulosclerosis in children and adults; idiopathic membranous nephropathy; idiopathic membranoproliferative glomerulonephritis; glomerulonephritis associated with infection; immunoglobulin A nephropathy and Henoch-Schönlein purpura nephritis; lupus nephritis; pauci-immune focal and segmental necrotizing glomerulonephritis; and anti-glomerular basement membrane antibody glomerulonephritis. We focuse our attention on progress in this topic in the last decade.

Keywords: glomerulonephritis; treatment; immunosuppression

Received: December 11, 2012; Accepted: January 22, 2013; Published: February 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Podracká Ľ, Matoušovic K. Practice guideline and trends for immunosuppressive treatment of glomerulonephritides according to KDIGO (Clinical Practice Guideline for Glomerulonephritis). Vnitr Lek. 2013;59(2):113-118.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Nephrotic syndrome in children: a randomized trial comparing two prednisone regimens in steroid-responsive patients who relapse early. Report of the international study of kidney disease in children. J Pediatr 1979; 95: 239-243. Go to original source... Go to PubMed...
    2. Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft für Pädiatrische Nephrologie. Arch Dis Child 1987; 62: 1102-1106.
    3. Bargman JM. Management of minimal lesion glomerulonephritis: Evidence-based recommendations. Kidney Int 1999; 55: (Suppl. 70): S3-S16. Go to original source... Go to PubMed...
    4. Podracká L, Böör A, Šasinka M. Cyclosporin A versus cyklofosfamid v liečbě nefrotického syndromu detí. Čas Lék Česk 2008; 147: 38-43. Go to PubMed...
    5. Dzúrik R, Šašinka M, Mydlík M et al. Nefrológia. Bratislava: Herba 2004.
    6. Burgess E. Management of focal segmental glomerulosclerosis. Evidence-based recommendations. Kidney Int 1999; 55: (Suppl. 70): S26-S32. Go to original source... Go to PubMed...
    7. Schieppati A, Mosconi L, Perna A et al. Prognosis of untreated patients with idiopathic membranous nephropathy. N Engl J Med 1993; 329: 85-89. Go to original source... Go to PubMed...
    8. Muirhead N. Management of idiopathic membranous nephropathy. Evidence-based recommendations. Kidney Int 1999; 55: (Suppl. 70): S47-S55. Go to original source... Go to PubMed...
    9. Imbasciati E, Cagnoli L, Case N et al. Controlled study of treatment of steroids and chlorambucil, in alternate months, for membranous nephropathy and focal glomerulosclerosis. Preliminary evaluation of the results. Minerva Nefrol 1980; 27: 571-575. Go to PubMed...
    10. Levin A. Management of membranoproliferative glomerulonephritis. Evidence-based recommendations. Kidney Int 1999; 55: (Suppl. 70): S41-S46. Go to original source... Go to PubMed...
    11. Nolin L, Courteau M. Management of IgA nephropathy. Evidence-based recommendations. Kidney Int 1999; 55: (Suppl. 70): S56-S62. Go to original source... Go to PubMed...
    12. Bedogna V, Valvo E, Casagrande P et al. Effects of ACE inhibition in normotensive patients with chronic glomerular disease and normal renal function. Kidney Int 1990; 38: 101-107. Go to original source... Go to PubMed...
    13. Donadio jr. JV, Grande JP, Bergstralh EJ et al. The long-term outcome of patients with IgA nephropathy treated with fish oil in a controlled trial. Mayo Nephrology Collaborative Group. J Am Soc Nephrol 1999; 10: 1772-1777. Go to original source... Go to PubMed...
    14. Jindal KK. Management of idiopathic crescentic and diffuse proliferative glomerulonephritis. Evidence-based recommendations. Kidney Int 1999; 55: (Suppl. 70): S33-S40. Go to original source... Go to PubMed...
    15. Coggins CH. Is membranous nephropathy treatable? Am J Nephrol 1981; 1: 219-221. Go to original source... Go to PubMed...
    16. Cameron JS, Healy MJ, Adu D. The Medical Research Council trial of short-term high-dose alternate day prednisolone in idiopathic membranous nephropathy with nephrotic syndrome in adults. The MRC Glomerulonephritis Working Party. Q J Med 1990; 74: 133-156. Go to original source...
    17. Bagga A, Sharma A, Srivastava RN. Levamisole therapy in corticosteroid-dependent nephrotic syndrome. Pediatr Nephrol 1997; 11: 415-417. Go to original source... Go to PubMed...
    18. Hodson EM, Willis NS, Craig JC. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev 2010; 11: CD003594. Go to original source... Go to PubMed...
    19. Kurman MR. Recent clinical trials with levamisole. Ann N Y Acad Sci 1993, 685: 269-277. Go to original source... Go to PubMed...
    20. Niaudet P, Drachman R, Gagnadoux MF et al. Treatment of idiopathic nephrotic syndrome with levamisole. Acta Paediatr Scand 1984; 73: 637-641. Go to original source... Go to PubMed...
    21. Glassock RJ. Therapy of idiopathic nephrotic syndrome in adults. A conservative or aggressive therapeutic approach? Am J Nephrol 1993; 13: 422-428. Go to original source... Go to PubMed...
    22. Schieppati A, Perna A, Zamora J et al. Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome. Cochrane Database Syst Rev 2004; 4: CD004293. Go to original source... Go to PubMed...
    23. Janeček M, Říhová Z, Tesař V et al. Naše zkušenosti s léčbou membranózní nefropatie cyklosporinem. Vnitř Lék 2005; 51: 504-509.
    24. Mestecky J, Raska M, Julian BA et al. IgA Nephropathy: Molecular Mechanisms of the Disease. Annu Rev Pathol. 2012, Oct 18. [Epub ahead of print].
    25. Hogg RJ, Lee J, Nardelli N et al. Southwest Pediatric Nephrology Study Group. Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol 2006; 1: 467-474. Go to original source... Go to PubMed...
    26. Dillon JJ. Fish oil therapy for IgA nephropathy: efficacy and interstudy variability. J Am Soc Nephrol 2001; 12: 846-847. Go to original source... Go to PubMed...
    27. Bohle A, Kressel G, Müller CA et al. The pathogenesis of chronic renal failure. Pathol Res Pract 1989; 185: 421-440. Go to original source... Go to PubMed...
    28. Matoušovic K, Rossmann P. Primary glomerulonephritis. Morphological and clinical aspects of diagnosis and prognosis. Praha: Academia 1994.
    29. Patel P, Pal S, Ashley C et al. Combination therapy with sirolimus (rapamycin) and tacrolimus (FK-506) in treatment of refractory minimal change nephropathy, a clinical case report. Nephrol Dial Transplant 2005; 20: 985-987. Go to original source... Go to PubMed...
    30. Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 2006; 354:1961-1963.
    31. Praga M, Hernández E, Montoyo C et al. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1992; 20: 240-248. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.